Pain related to intravitreal injections for age-related macular degeneration: a qualitative study of the perspectives of patients and practitioners

被引:2
|
作者
Yiallouridou, Christina [1 ]
Acton, Jennifer H. [1 ]
Banerjee, Sanjiv [2 ]
Waterman, Heather [3 ]
Wood, Ashley [1 ]
机构
[1] Cardiff Univ, Sch Optometry & Vis Sci, Cardiff, Wales
[2] Cardiff & Vale Univ Hlth Board, Ophthalmol, Cardiff, Wales
[3] Cardiff Univ, Healthcare Sci, Cardiff, Wales
来源
BMJ OPEN | 2023年 / 13卷 / 08期
关键词
QUALITATIVE RESEARCH; PAIN MANAGEMENT; OPHTHALMOLOGY; NEEDLE SIZE; RANIBIZUMAB; EXPERIENCES; ANXIETY; ANESTHESIA; FEAR;
D O I
10.1136/bmjopen-2022-069625
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
ObjectivesOcular pain is a commonly reported finding in the intravitreal injection procedure, but post-injection experiences and patient adherence to treatment remain underexplored. We therefore aimed to identify key variations in the intravitreal injection procedure that may influence pain, and to gain insights into the post-injection experience and treatment adherence from the perspective of patients and practitioners. DesignQualitative semistructured interview study using reflexive thematic analysis of transcripts. SettingHospital Eye Clinic in Wales, UK. Interviews were conducted between May and September 2019. ParticipantsPurposive sample of patients aged & GE;50 years with neovascular age-related macular degeneration and no other retinal pathology who had received at least six intravitreal injections, and practitioners including ophthalmologists, registered nurses and optometrists who performed intravitreal injections at the research site. ResultsData saturation was reached with 21 interviews: 14 patients and 7 practitioners. Three main themes were identified from the analysis: fear of losing eyesight and treatment anxiety influence patient adherence to treatment, variability in pain experience during treatment, and post-injection experience and impact on patient recovery. To reassure patients feeling apprehensive about the injections, practitioners promoted safety and trust, and used techniques to manage anxiety. Key variations that may influence pain identified were application of antiseptic or anaesthetic, injecting methods and communication. During injection, patients reported a dull-aching and sharp pain, contrary to practitioners' perspective of feeling a 'pressure'. Patients described prolonged soreness and irritation of up to 36 hours post-injection affecting their sleep and recovery. ConclusionEstablishing rapport supported patients to recognise the necessity of ongoing treatment to prevent sight loss; however, inadequate pain management led to undesirable outcomes. Practitioners should use pain assessment tools during and immediately after injection and provide ongoing consistent information to help patients manage pain at home.
引用
收藏
页数:12
相关论文
共 50 条
  • [41] Aflibercept for Intravitreal Injection In Neovascular Age-Related Macular Degeneration
    Frampton, James E.
    DRUGS & AGING, 2012, 29 (10) : 839 - 846
  • [42] Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration
    Avery, RL
    Pieramici, DJ
    Rabena, MD
    Castellarin, AA
    Nasir, MA
    Giust, MJ
    OPHTHALMOLOGY, 2006, 113 (03) : 363 - 372
  • [43] Intravitreal conbercept injection for neovascular age-related macular degeneration
    Wu, Bing-Hui
    Wang, Bing
    Wu, Hui-Qin
    Chang, Qin
    Lu, Hui-Qin
    INTERNATIONAL JOURNAL OF OPHTHALMOLOGY, 2019, 12 (02) : 252 - 257
  • [44] Efficacy of intravitreal aflibercept in Japanese patients with exudative age-related macular degeneration
    Saito, Masaaki
    Kano, Mariko
    Itagaki, Kanako
    Sekiryu, Tetsuju
    JAPANESE JOURNAL OF OPHTHALMOLOGY, 2017, 61 (01) : 74 - 83
  • [45] Efficacy of intravitreal aflibercept in Japanese patients with exudative age-related macular degeneration
    Masaaki Saito
    Mariko Kano
    Kanako Itagaki
    Tetsuju Sekiryu
    Japanese Journal of Ophthalmology, 2017, 61 : 74 - 83
  • [46] Intravitreal Therapy in Bilateral Neovascular Age-Related Macular Degeneration
    Barthelmes, Daniel
    Walton, Richard J.
    Arnold, Jennifer J.
    Mcallister, Ian L.
    Simpson, Judy M.
    Campain, Anna
    Hunyor, Alex P.
    Guymer, Robyn
    Essex, Rohan W.
    Morlet, Nigel
    Gillies, Mark C.
    OPHTHALMOLOGY, 2014, 121 (10) : 2073 - 2074
  • [47] Aflibercept for Intravitreal InjectionIn Neovascular Age-Related Macular Degeneration
    James E. Frampton
    Drugs & Aging, 2012, 29 : 839 - 846
  • [48] Patient perspectives and barriers in the treatment of neovascular age-related macular degeneration in Denmark: a qualitative study
    Thinggaard, Benjamin Sommer
    Pedersen, Maria
    Sorensen, Torben Lykke
    Grauslund, Jakob
    Stokholm, Lonny
    BMJ OPEN, 2023, 13 (11):
  • [49] PHARMACOKINETIC STUDY OF INTRAVITREAL AFLIBERCEPT IN HUMANS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
    Do, Diana V.
    Rhoades, William
    Nguyen, Quan Dong
    RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2020, 40 (04): : 643 - 647
  • [50] Intravitreal bevacizumab therapy for neovascular age-related macular degeneration:: a pilot study
    Abraham-Marin, Maura Lucy
    Cortes-Luna, Carlos Fernando
    Alvarez-Rivera, Griselda
    Hernandez-Rojas, Myriam
    Quiroz-Mercado, Hugo
    Morales-Canton, Virgilio
    GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2007, 245 (05) : 651 - 655